Psychedelic-assisted therapy is becoming central in modern medicine, moving from fringe to mainstream, especially in the treatment of mental and physical health disorders. This shift is highlighted by a recent initiative from the National Institutes of Health (NIH), which focuses on integrating psychedelics into the treatment of older adults with chronic pain—a group frequently facing treatment-resistant conditions and limited therapeutic options.
Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Older Adults (UG3/UH3 Clinical Trial Required) https://t.co/QQJ84LcfkJ
— NIH Funding (@NIHFunding) April 24, 2024
The Psychedelic-Assisted Therapy Approach
The NIH recently announced a plan to invest $8.4 million in research exploring psychedelic-assisted therapy (PAT) as a novel treatment for chronic pain among older adults. With an aging population that reports a high prevalence of chronic pain, innovative solutions are more crucial than ever.
Traditionally, treatments involving acetaminophen, NSAIDs, opioids, and behavioral therapy have been the go-to. Yet, they remain complex and often inadequate, leaving a substantial portion of the elderly population in continued discomfort with multitudes of ailments.
This marks a shift towards exploring the therapeutic potential of substances traditionally overlooked by the medical community. The funded clinical trials will focus on classic psychedelics like psilocybin, LSD, DMT, and mescaline, as well as similar compounds like MDMA, moving away from cannabis and ketamine.
Why Focus on Older Adults?
Approximately 40% of older Americans live with chronic pain, a condition that not only diminishes the quality of life but also contributes to other serious health issues such as depression, anxiety, sleep disturbances, and even suicidal ideation, as outlined by the announcement. Chronic pain also places a substantial economic burden on society due to increased healthcare utilization and premature disability claims.
Despite the prevalence and impact of chronic pain, conventional pharmacologic treatments offer limited relief and come with significant risks of adverse effects, especially for older adults. This demographic is often more susceptible to side effects and may have contraindications for conventional pain medications due to co-occurring health conditions.
The NIH-funded research seeks to explore PAT’s safety and efficacy in treating chronic pain among older adults through a two-phase clinical trial network. The first phase focuses on safety and pharmacokinetic properties in healthy older adults, while the second phase expands to include those with chronic pain conditions.
Historically, Indigenous cultures have used sacred plant medicines for millennia, integrating these substances into ceremonial healing practices. Only in recent decades has Western science begun to recognize and study the therapeutic potential of psychedelics.
Now, with regulatory bodies like the FDA actively developing frameworks for the approval of these compounds, the door to novel and potentially life-changing treatments is opening wider.
Moving Forward
With the application window for this new grant money slated for September 10th to October 10th and the earliest start date for the work set for July 2025, we could be approaching an important moment in the development of psychedelic-assisted therapy.
This initiative is not just about finding an alternative treatment for chronic pain; it’s about reevaluating our understanding of medicine, healing, and the potential of compounds that have, until now, been largely marginalized. It heralds a shift towards more holistic and integrative approaches to health, underscoring the importance of mental, emotional, and physical well-being across the lifespan.
